Recent progress in our understanding of the pathogenesis of primary Sjögren's syndrome (pSS) and the development of indices to measure disease activity in patients with this condition, offer us ample possibilities for treatment with biologic DMARDs. New biomarkers further aid selection of patients with pSS for appropriate treatment options.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ramos-Casals, M., Brito-Zeron, P., Siso-Almirall, A., Bosch, X. & Tzioufas, A. G. Topical and systemic medications for the treatment of primary Sjögren's syndrome. Nat. Rev. Rheumatol. 8, 399–411 (2012).
Maria, N. I. et al. MxA as a clinically applicable biomarker for identifying systemic interferon type I in primary Sjögren's syndrome. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2012-202552.
Seror, R. et al. EULAR Sjögren's syndrome patient reported index (ESSPRI): Development of a consensus patient index for primary Sjögren's syndrome. Ann. Rheum. Dis. 70, 968–972 (2011).
Seror, R. et al. EULAR Sjögren's syndrome disease activity index: Development of a consensus systemic disease activity index for primary Sjögren's syndrome. Ann. Rheum. Dis. 69, 1103–1109 (2010).
Moerman, R. V. et al. EULAR Sjögren's syndrome disease activity index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2013-203736.
Pollard, R. P. et al. Predominantly proinflammatory cytokines decrease after B cell depletion therapy in patients with primary Sjögren's syndrome. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2013-203447.
Ronnblom, L. & Eloranta, M. L. The interferon signature in autoimmune diseases. Curr. Opin. Rheumatol. 25, 248–253 (2013).
Gottenberg, J. E. et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome. Proc. Natl Acad. Sci. USA 103, 2770–2775 (2006).
Hjelmervik, T. O., Petersen, K., Jonassen, I., Jonsson, R. & Bolstad, A. I. Gene expression profiling of minor salivary glands clearly distinguishes primary Sjögren's syndrome patients from healthy control subjects. Arthritis Rheum. 52, 1534–1144 (2005).
Raterman, H. G. et al. The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients. Arthritis Res. Ther. 14, R95 (2012).
Acknowledgements
We would like to thank A. Vissink and M. Boers for critical reading of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Kroese, F., Bootsma, H. New biomarker for Sjögren's syndrome—time to treat patients. Nat Rev Rheumatol 9, 570–572 (2013). https://doi.org/10.1038/nrrheum.2013.143
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2013.143
